Research subjects in clinical trials must be informed of certain financial arrangements or prior misconduct of clinical investigators, the FDA has announced.

The disclosures are part of a series of mostly routine changes to the Bioresearch Monitoring Information System that tracks clinical investigators’ compliance with FDA regulations. The agency published a notice of changes Jan. 9 in the Federal Register. The changes in disclosures to research subjects include:

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access